Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings data on Tuesday. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Trading Down 1.3 %

Aura Biosciences stock traded down $0.14 during trading on Wednesday, hitting $10.51. The company had a trading volume of 19,066 shares, compared to its average volume of 175,060. The company’s 50 day simple moving average is $9.69 and its 200-day simple moving average is $8.49. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The stock has a market cap of $521.40 million, a price-to-earnings ratio of -6.06 and a beta of 0.33.

Analysts Set New Price Targets

Several analysts recently issued reports on AURA shares. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. JMP Securities boosted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Scotiabank raised their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Finally, Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and a consensus target price of $23.00.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 9,200 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the sale, the insider now directly owns 320,647 shares in the company, valued at $3,443,748.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Los Pinos Elisabet De sold 9,200 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,259 shares of company stock worth $780,699 over the last ninety days. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.